Lindbrook Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Lindbrook Capital’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$13	Hold	29	–	–	﹤0.01%	2773
2024 Q4	$15	Hold	29	–	–	﹤0.01%	2767
2024 Q3	$26	Hold	29	–	–	﹤0.01%	2811
2024 Q2	$29	Hold	29	–	–	﹤0.01%	2744
2024 Q1	$43	Sell	29 -1,725	-98%	-$1.96K	﹤0.01%	2625
2023 Q4	$1.91K	Hold	1,754	–	–	﹤0.01%	2277
2023 Q3	$2.07K	Hold	1,754	–	–	﹤0.01%	2113
2023 Q2	$2.47K	Hold	1,754	–	–	﹤0.01%	2067
2023 Q1	$2.63K	Hold	1,754	–	–	﹤0.01%	2124
2022 Q4	$2.05K	Hold	1,754	–	–	﹤0.01%	2219
2022 Q3	$2K	Hold	1,754	–	–	﹤0.01%	2089
2022 Q2	$3K	Hold	1,754	–	–	﹤0.01%	1800
2022 Q1	$3K	Hold	1,754	–	–	﹤0.01%	1837
2021 Q4	$4K	Buy	1,754 +1,725	+5,948%	+$4.04K	﹤0.01%	1581
2021 Q3	$0	Hold	29	–	–	﹤0.01%	1936
2021 Q2	$0	Hold	29	–	–	﹤0.01%	1958
2021 Q1	$0	Hold	29	–	–	﹤0.01%	1906
2020 Q4	$0	Hold	29	–	–	﹤0.01%	1827
2020 Q3	$0	Hold	29	–	–	﹤0.01%	1802
2020 Q2	$0	Hold	29	–	–	﹤0.01%	1809
2020 Q1	$0	Hold	29	–	–	﹤0.01%	1773
2019 Q4	$0	Hold	29	–	–	﹤0.01%	1525
2019 Q3	$0	Hold	29	–	–	﹤0.01%	1486
2019 Q2	$0	Hold	29	–	–	﹤0.01%	1457
2019 Q1	$0	Buy	+29	New	+$36	﹤0.01%	1456

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lindbrook Capital's LCTX Position: Q1 2025 in Review

Lindbrook Capital held its Lineage Cell Therapeutics (LCTX) position steady in Q1 2025 at 29 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

Lindbrook Capital first reported a position in LCTX in Q1 2019 and has held it in 25 quarters since. The position peaked at $4K in Q4 2021. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

Lindbrook Capital held 29 shares of Lineage Cell Therapeutics worth $13 as of Q1 2025.
Lindbrook Capital left its Lineage Cell Therapeutics share count unchanged in Q1 2025.
Lineage Cell Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2773 holding.
Lindbrook Capital first reported a position in Lineage Cell Therapeutics in Q1 2019 and has held it in 25 quarters since.
Lindbrook Capital's Lineage Cell Therapeutics position peaked at $4K in Q4 2021.
127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.